Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaSandrine Degryse, Matthew D. Dun|Leukemia|2017Cited by 88